The most common treatment-related AEs between pembrolizumab and nivolumab groups were fatigue (12.0% versus 10.5%), rash (8.0% versus 8.4%), increased aspartate/alanine aminotransferase levels (8.0% versus 7.4%), diarrhea (4.0% versus 4.2%), pruritus (4.0% versus 4.2%), decreased appetite (4.0% versus 3.2%), hypothyroidism (4.0% versus 3.2%), decreased body weight (4.0% versus 2.1%), nausea (4.0% versus 2.1%), and hypersensitivity/infusion-related reaction (4.0% versus 2.1%). The gene discussed is GPT; the disease is hypothyroidism.